Tag Archives: healthcare

A Bright Future for Orphan Disease Indications

Chart

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved drugs in the BioMedTracker database with an orphan indication designation. Our research found that 2012 saw the greatest number of approvals of therapies for orphan indications going back all the way to 2000 (This count includes previously approved drugs with new, orphan indication approvals).   Overall, 24 therapies were approved in orphan indications last year, including drugs for Anthrax, Gaucher’s Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , ,

Navigating the Rare Disease World

Susan Ruediger

The international orphan drug marketplace is expected to grow some 30 percent by 2014, fueled by the entrance of big pharmaceutical companies and U.S. legislation favoring development and coverage. This growth promises to improve the health of patients with debilitating and life-threatening disorders. Hoping to further the rare disease dialogue and relationship building opportunities, the 2013 Orphan Disease Forum will provide unique perspective on the orphan drug marketplace, regulatory considerations and much more. Operating within Read More >

Events  |  2 Comments  |  Email This Post
Tags: , , , , , , , ,

Rare Disease Day: Families and Advocacy Groups Drive Treatments for Rare Diseases

Gavin and Bella Today, we celebrate Rare Disease Day to recognize the path to treatments and cures is paved by families and caregivers working with advocacy groups, medical advisors, and dedicated researchers. Of the many people touched by and involved in the world of rare diseases, patients and their families are inarguably the most passionate advocates for rare disease research. When their disease-focused family foundations work together, pool their funds, and align their efforts, the results can be Read More >
Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Renewing the Project BioShield Act: What Has It Bought and Wrought?

Syringe

In the next several months, the U.S. Government will decide whether to continue the funding and authorities associated with Project BioShield, which expanded the U.S. stockpile of medical countermeasures (MCMs) for potential chemical, biological, radiological and nuclear (CBRN) attacks. Congress established Project BioShield in 2004 and provided $5.68B for procurement over 10 years. Two years later, it created the Biomedical Advanced Research and Development Authority (BARDA) to oversee BioShield’s advanced development and procurement efforts. To Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

How the Biotechnology Industry Can Combat Doping in Sports

Track

Biotechnology companies work every day to solve some of our biggest global challenges – fighting disease, hunger and pollution. Yet, we in the biotech industry are strongly aware that our products can also be misused in the wrong hands. The same medicines that can be used to help children with devastating genetic deficiencies and growth disorders, or to help a chemotherapy patient combat cancer, can also be abused by healthy athletes to gain an unfair Read More >

Jim's Corner  |  1 Comment  |  Email This Post
Tags: , , , , , ,